Allowing NHS doctors to offer a “cheap, safe and effective” drug to treat a common eye condition could release up to A 102 million a year for other patient services but its access is being blocked by the pharmaceutical company behind it, health experts have claimed. Wet age-related macular degeneration is currently treated with Lucentis, but clinical leaders want Avastin, which is currently licensed for cancer treatment, to be given to wet AMD patients.